奇正藏药(002287) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 403,015,309.71, representing a 10.39% increase compared to CNY 365,098,756.48 in the same period last year[5]. - Net profit attributable to shareholders decreased by 22.35% to CNY 75,679,793.49 from CNY 97,460,837.34 year-on-year[5]. - The basic and diluted earnings per share fell by 22.47% to CNY 0.1425 from CNY 0.1838 in the same quarter last year[5]. - Net profit for the current period was ¥75,094,519.94, a decrease of 24.0% from ¥98,694,178.45 in the previous period[23]. - Total operating revenue for the current period reached ¥403,015,309.71, an increase of 10.4% compared to ¥365,098,756.48 in the previous period[22]. - Total operating costs amounted to ¥323,360,068.03, up from ¥299,888,820.46, reflecting a growth of 7.8%[22]. Cash Flow - The net cash flow from operating activities significantly improved to CNY 255,818,548.95, a 233.71% increase from a negative CNY 191,328,489.83 in the previous year[5]. - Cash flow from operating activities increased significantly to ¥779,219,257.76 from ¥218,276,103.92, marking a growth of approximately 257%[24]. - Cash inflow from investment activities rose to ¥649,590,484.38 from ¥310,023,126.95, an increase of about 109%[25]. - Net cash flow from investment activities improved to ¥101,593,821.93 from a negative ¥276,882,207.67[25]. - Cash inflow from financing activities was recorded at ¥552,027,349.50, up from ¥439,200,000.00[25]. - The net increase in cash and cash equivalents was ¥333,498,493.12, compared to a decrease of ¥32,301,704.19 in the previous period[25]. - The ending balance of cash and cash equivalents increased to ¥523,089,986.62 from ¥356,202,070.72[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,714,750,640.52, down 1.11% from CNY 6,790,420,367.07 at the end of the previous year[5]. - The company’s total liabilities decreased by 1.08% to CNY 4,020,668,719.25 from CNY 4,064,375,038.17 at the end of the previous year[5]. - Total liabilities decreased to ¥2,645,695,845.76 from ¥2,677,107,646.35, a reduction of 1.2%[20]. - The total equity attributable to shareholders of the parent company was ¥4,020,668,719.25, down from ¥4,064,375,038.17, a decrease of 1.1%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,704[13]. - Gansu Qizheng Industrial Group Co., Ltd. holds 68.64% of shares, totaling 364,546,473 shares, with 23,913,456 shares pledged[13]. - Tibet Yutuo Cultural Development Co., Ltd. holds 18.53% of shares, totaling 98,395,215 shares, with 3,000,000 shares pledged[13]. - The company plans to repurchase shares with a total amount not less than RMB 90 million and not exceeding RMB 160 million, at a maximum price of RMB 31.65 per share[15]. - As of March 31, 2025, the company has repurchased 148,800 shares, accounting for 0.0280% of the total share capital, with a total transaction amount of RMB 3,380,561[16]. Investment and Other Income - The company reported a significant increase in cash and cash equivalents, with a net increase of CNY 333,498,493.12, reflecting a 1132.45% improvement from a decrease of CNY 32,301,704.19 in the prior year[11]. - The fair value changes of financial assets resulted in a loss of CNY 18,669,206.06, a decrease of 33.61% compared to the previous year[9]. - The company’s investment income showed a significant decline, reporting a loss of CNY 3,334,451.19 compared to a profit of CNY 10,285,742.77 in the same period last year[9]. - Research and development expenses were ¥11,472,526.65, slightly down from ¥12,018,942.57, indicating a focus on cost management[22]. - Other comprehensive income after tax showed a negative net amount of ¥54,508.06, contrasting with a positive amount of ¥63,746.45 previously[23]. Operational Insights - The company did not report any new product launches or technological advancements during the conference call[26]. - The first quarter report was not audited, indicating a potential area for further scrutiny[26].